Targeting a specific pathway to overcome treatment resistance in ovarian cancer
Targeting Wnt signaling in therapy-resistant ovarian cancer
This study is looking at why some ovarian cancer cells stop responding to a treatment called PARP inhibitors, and it aims to find new ways to make these treatments work better by exploring a specific pathway in the cells and testing a new drug that could boost the immune response against the cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10896186 on NIH RePORTER |
What this research studies
This research investigates how certain ovarian cancer cells become resistant to a type of treatment known as PARP inhibitors. By using specialized cell lines and patient-derived models, the team aims to understand the role of the Wnt signaling pathway in this resistance. They will explore how this pathway affects the immune response to tumors and test a new drug that targets Wnt signaling in combination with immune checkpoint blockade therapy. The goal is to find ways to enhance the effectiveness of treatments for patients with resistant ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with high-grade serous ovarian cancer who have developed resistance to PARP inhibitors.
Not a fit: Patients with other types of ovarian cancer or those who have not received PARP inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with therapy-resistant ovarian cancer.
How similar studies have performed: Other research has shown promising results in targeting similar pathways to enhance cancer treatment, indicating potential for success in this approach.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Bitler, Benjamin G — University of Colorado Denver
- Study coordinator: Bitler, Benjamin G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.